Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + acellular pertussis + hepatitis B + haemophilus influenzae type b conjugate vaccine
- Development stage
- Phase 3
- Lead developer
- MCM Vaccine Co
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The diphtheria + tetanus + acellular pertussis + hepatitis B + haemophilus influenzae type b conjugate vaccine (DTaP-HB-PRP~T) is a pentavalent combination vaccine developed for pediatric immunization. It provides active immunity against five major childhood pathogens: *Corynebacterium diphtheriae*, *Clostridium tetani*, *Bordetella pertussis*, Hepatitis B virus (HBV), and *Haemophilus influenzae* type b (Hib). The vaccine utilizes acellular pertussis (aP) antigens, which typically include pertussis toxoid and filamentous hemagglutinin, offering a improved safety profile with fewer local reactions compared to whole-cell pertussis (wP) vaccines. The Hib component is a conjugate vaccine consisting of the polyribosylribitol phosphate (PRP) capsular polysaccharide covalently linked to a tetanus toxoid (T) carrier protein to ensure a T-cell dependent immune response in young infants. By combining these five components into a single injection, the vaccine aims to simplify complex immunization schedules, reduce the number of clinic visits, and improve overall vaccination coverage.
- Brand names
- VaxelisInfanrix hexa
- Other names
- DTaP-HepB-Hib vaccinepentavalent DTaP-HepB-Hib vaccinediphtheria-tetanus-acellular pertussis-hepatitis B-Haemophilus influenzae type b vaccine
02
Targets
FHA (Filamentous hemagglutinin)HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria + tetanus + acellular pertussis + hepatitis B + haemophilus influenzae type b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + acellular pertussis + hepatitis B + haemophilus influenzae type b conjugate vaccine.